Boise、IDにおける非小細胞肺癌の臨床試験
Boiseとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する14件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Saint Alphonsus Cancer Care Center-Boise, Boise
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Saint Luke's Cancer Institute - Boise, Boise
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
被験者募集中第2相
- Saint Alphonsus Cancer Care Center-Boise, Boise
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Boise
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
被験者募集中第3相
- Saint Alphonsus Regional Medical Center - Boise, Boise
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- St. Luke's Cancer Institute, Boise
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
被験者募集中第3相
- Saint Luke's Cancer Institute - Boise, Boise
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Saint Alphonsus Cancer Care Center-Boise, Boise
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
被験者募集中第3相
- Saint Alphonsus Health System, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Saint Alphonsus Cancer Care Center-Boise, Boise
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2/3相
- Saint Alphonsus Cancer Care Center-Boise, Boise
- Saint Luke's Cancer Institute - Boise, Boise
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Saint Alphonsus Cancer Care Center-Boise, Boise
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Saint Alphonsus Cancer Care Center-Boise, Boise
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Boise
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Boiseにおける他の研究
- 肺がん11件の研究
- 急性骨髄性白血病8件の研究
- 前立腺がん8件の研究
- 結腸癌7件の研究
- 大腸癌6件の研究
- 呼吸窮迫症候群6件の研究
- 乳がん6件の研究
- 悪性黒色腫6件の研究
- バーキットリンパ腫5件の研究
- 膵臓がん4件の研究
- 骨髄増殖性腫瘍4件の研究
- 骨髄異形成症候群4件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。